Cargando…
156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset
Autores principales: | Pira, A., Mariotti, F., Moro, F., Panebianco, A., Pallotta, S., Didona, B., Di Zenzo, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106941/ http://dx.doi.org/10.1016/j.jid.2023.03.157 |
Ejemplares similares
-
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis
por: Moro, Francesco, et al.
Publicado: (2022) -
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
por: Maronese, Carlo Alberto, et al.
Publicado: (2022) -
The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets
por: Maglie, Roberto, et al.
Publicado: (2023) -
Bullous Pemphigoid: Trigger and Predisposing Factors
por: Moro, Francesco, et al.
Publicado: (2020) -
Case report: bullous pemphigoid development underlies dystrophic epidermolysis bullosa disease worsening
por: Di Zenzo, Giovanni, et al.
Publicado: (2022)